Share the post "Ipca Laboratories : Q4 2024 Financial Quarterly Report : YoY Sales Up 34.49 %, QoQ Down 0.97 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 34.49 % in the past year, decrease in net sales/revenue by -0.97 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -48.18 %, Marginal decrease of -16.63% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for Ipca Laboratories Ltd.. Profit dropped by -98.3 % Year to Year, Ipca Laboratories Ltd.’s profitability dropped by -99.4 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -22.19 % Year to Year. EPS decreased by -66.85 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1511.63 Cr | Rs. 2052.86 Cr | Rs. 2033.01 Cr | -0.97 % | + 34.49 % |
Expenses | Rs. 1330.59 Cr | Rs. 1721.53 Cr | Rs. 1711.11 Cr | -0.61 % | + 28.6 % |
Operating Profit | Rs. 181.04 Cr | Rs. 331.33 Cr | Rs. 321.9 Cr | -2.85 % | + 77.81 % |
OPM % | 11.98 % | 16.14 % | 15.83 % | -0.31 % | + 3.85 % |
Other Income | Rs. 33.46 Cr | Rs. 20.8 Cr | Rs. 17.34 Cr | -16.63 % | -48.18 % |
Interest | Rs. 18.45 Cr | Rs. 33.4 Cr | Rs. 29.37 Cr | -12.07 % | + 59.19 % |
Depreciation | Rs. 69.54 Cr | Rs. 99.5 Cr | Rs. 98.13 Cr | -1.38 % | + 41.11 % |
Profit before tax | Rs. 126.51 Cr | Rs. 219.23 Cr | Rs. 211.74 Cr | -3.42 % | + 67.37 % |
Tax % | 37.37 % | 22.93 % | 96.2 % | + 73.27 % | + 58.83 % |
Net Profit | Rs. 78.14 Cr | Rs. 221 Cr | Rs. 1.33 Cr | -99.4 % | -98.3 % |
EPS in Rs | Rs. 3.02 | Rs. 7.09 | Rs. 2.35 | -66.85 % | -22.19 % |
Today, we’re looking at Ipca Laboratories Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 34.49 %. However, it did see a marginal slip of -0.97 % from the previous quarter. Expenses decreased slightly by -0.61 % quarter-on-quarter, aligning with the annual rise of 28.6 %. Operating profit, while up 77.81 % compared to last year, faced a quarter-on-quarter dip of -2.85 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 3.85 %, but a shrinkage of -0.31 % sequentially. Other income fell by -16.63 % compared to the last quarter, despite an annual decline of -48.18 %. Interest expenses dropped significantly by -12.07 % from the previous quarter, yet the year-over-year increase remains at a moderate 59.19 %. Depreciation costs fell by -1.38 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 41.11 %. Profit before tax grew annually by 67.37 % but saw a reduction from the preceding quarter by -3.42 %.
Tax expenses as a percentage of profits increased slightly by 58.83 % compared to last year, with a more notable quarter-on-quarter increase of 73.27 %. Net profit fell by -98.3 % year-on-year but witnessed a -99.4 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -22.19 % but a quarterly fall of -66.85 %. In summary, Ipca Laboratories Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1511.63 Cr | Rs. 2052.86 Cr | Rs. 2033.01 Cr | -0.97 % | + 34.49 % |
Expenses | Rs. 1330.59 Cr | Rs. 1721.53 Cr | Rs. 1711.11 Cr | -0.61 % | + 28.6 % |
Operating Profit | Rs. 181.04 Cr | Rs. 331.33 Cr | Rs. 321.9 Cr | -2.85 % | + 77.81 % |
Net Profit | Rs. 78.14 Cr | Rs. 221 Cr | Rs. 1.33 Cr | -99.4 % | -98.3 % |
EPS in Rs | Rs. 3.02 | Rs. 7.09 | Rs. 2.35 | -66.85 % | -22.19 % |
In reviewing Ipca Laboratories Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 34.49 % year-on-year growth, although there was a slight dip of -0.97 % from the previous quarter. Expenses rose by 28.6 % compared to the previous year, with a decrease of -0.61 % quarter-on-quarter. Operating Profit surged by 77.81 % annually, and saw a -2.85 % decrease from the last quarter.
Net Profit showed yearly decrease of -98.3 %, and experienced a -99.4 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -22.19 % annually, however dipped by -66.85 % compared to the last quarter. In essence, while Ipca Laboratories Ltd. faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.